Sleep Apnea Devices Market size was valued at USD 3.8 billion in 2021, growing at a CAGR of 6.2% during the forecast period 2022-2028. Global Sleep Apnea Devices market is a chronic disorder, characterized with repetitive obstructions in breathing during sleep. Major symptoms include snoring, gasping or choking. Long-term health problems associated with OSA include cardiovascular disorders, memory and cognitive problems, glaucoma, depression and mood disorders. Polysomnography and portable home sleep diagnostic devices are enabling diagnose the Obstructive sleep apnea (OSA). First line therapy for involves positive airway devices(PAP). If patients do not respond to the PAP therapy, second-line treatment includes dental appliances and surgery. Rapid traction in the global geriatric population coupled with increased obesity levels enables to increase the prevalence of sleep apnea. The world is experiencing growth in the number and proportion of old age people. As per WHO, the number of people aged 60 years or over is projected to grow approximately 56 % between 2015 to 2030. According to estimates, a prevalence of OSA is approximately 3% to 7% of the adult men and 2 to 5% of adult women. Moreover, 80% of the patients with moderate to severe sleep apnea may be undiagnosed.
In August 2016, Fisher & Paykel Healthcare launched ‘F&P Brevida nasal pillow mask’ for the treatment of OSA. The product will be initially available in Australia & New Zealand followed by Canada and Europe